Any content you receive is for information purposes only. Always conduct your own research. | *Sponsored | See Why (CODX) Will Be Topping Our Watchlist Tomorrow Morning—Friday, March 20th, 2026. | | March 19, 2026 | A $4.30B market projected to hit $7.09B by 2030 — fueled by surging demand for rapid, accessible diagnostic testing. One small-cap name is quietly stacking international patent protection while preparing to commercialize its point-of-care PCR platform across multiple continents. | Per MarketsandMarkets, the point-of-care molecular diagnostics space is expanding fast — and Co-Diagnostics, Inc. (NASDAQ: CODX) just secured another layer of global IP protection. The Japan Patent Office granted Patent No. 7797537 covering 34 claims for the company's automated biological analysis system, according to the March 12 press release. This follows an Australian patent grant in late 2025, and arrives as (CODX) nears commercialization of its India manufacturing joint venture. | Here's why that matters: the Japan Patent Office is considered one of the world's most rigorous in its review process. A 34-claim patent approval there could signal genuine innovation — not just incremental improvement. | Co-Diagnostics, Inc. (NASDAQ: CODX) is topping our watchlist tomorrow morning— Friday, March 20, 2026. | According to Yahoo Finance, (CODX) has approximately 1.94M shares in its public float—with a float that small, the potential exists for big moves if demand begins to shift. | In fact, (CODX) recently made an approximate 108% move, practically overnight, from around $2.11 on March 9 to $4.40 the very next day. | Pioneering Point-of-Care PCR Innovation | Co-Diagnostics develops and manufactures state-of-the-art molecular diagnostic technologies. | The company's Co-Dx PCR Platform™ leverages its patented Co-Primers® technology for highly sensitive nucleic acid detection. | Its automated system — now protected by 34 patent claims — encompasses the Co-Dx PCR Pro® instrument and proprietary test cups for point-of-care settings. | Clinical evaluations for Co-Dx™ PCR Flu A/B, COVID-19, RSV Test Kit are underway to support FDA 510(k) clearance submission. | Recent Milestones Worth Watching | Japan Patent Granted: Per the March 12 press release, the JPO granted Patent No. 7797537 covering 34 claims for automated biological analysis. India Manufacturing License: CoSara Diagnostics received CDSCO license to manufacture the CoSara PCR Pro™ instrument, per the February 5 announcement — the final license required before commercialization. ISO 13485 Certification: CoSara's Vadodara facility received ISO 13485:2016 certification, per the February 4 release — vital for regulatory submission and qualifying for India's 'Make in India' initiative. Australian Patent Protection: The Australian Patent Office granted Patent No. AU2022270084A1, per the December announcement.
| 7 Reasons (CODX) Tops Our Watchlist | Small Float Dynamics: With approximately 1.94M shares in its public float per Yahoo Finance, (CODX) could potentially see volatility accelerate quickly. Fresh Patent Protection: The Japan Patent Office just granted a comprehensive 34-claim patent, reinforcing global IP protection. India Commercialization Path: CoSara's CDSCO license and ISO certification position (CODX) for expanded market access where gold-standard PCR diagnostics are most needed. Proprietary Technology Edge: The patented Co-Primers® technology delivers gold-standard PCR accuracy in a compact, user-friendly device. Global Expansion Footprint: Partnerships span the U.S., India (CoSara JV), Saudi Arabia and 18 MENA countries (CoMira JV), plus patent protection in Japan and Australia. FDA Pathway Progress: Clinical evaluations are underway to support FDA 510(k) clearance — a near-term potential catalyst. Recent Momentum: (CODX) recently made an approximate 108% move, practically overnight, from around $2.11 on March 9 to $4.40 the very next day.
| Pull Up (CODX) Before Tomorrow Morning… | From its small float and fresh Japan patent grant to India manufacturing milestones and FDA pathway progress, (CODX) continues to stand out among molecular diagnostics innovators. With technologies aligned with a market projected to reach $7.09B by 2030, (CODX) sits at the intersection of innovation and accessibility. | We will have all eyes on (CODX) tomorrow morning—Friday, March 20th, 2026. | | Sincerely, | Dean Knightly
Editor, Trading Ideas | | Sources: | | | TradingIdeas.app ("TradingIdeas" or "TI" ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and TI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile TI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. | Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 03/19/2026 and ending on 03/20/2026 to publicly disseminate information about (CODX:US) via digital communications. Under this agreement, JRZ Capital LLC has paid TD Media LLC seventy five thousand USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. | Neither TD Media LLC and their member own shares of (CODX:US). | Please see important disclosure information here: https://tradingideas.app/disclosure/codx-GguGM/#details |
|
